Table 1. Unadjusted and adjusted baseline characteristics of cancer survivors (n=22,907) and non-cancer patients (n=247,182).
| Characteristic | Non-cancer patients, unadjusted % | Cancer patients, unadjusted % | Non-cancer patients, IPTW adjusted % | Cancer survivors, IPTW adjusted % | IPTW standardized difference, % |
|---|---|---|---|---|---|
| Sex (female) | 37.5 | 41.6 | 37.8 | 38.9 | 2.2 |
| Age, years | |||||
| < 45 | 6.5 | 0.6 | 5.8 | 5.8 | 0.19 |
| 45-64 | 37.3 | 11.6 | 35.2 | 34.2 | 2.1 |
| > 65 | 56.2 | 87.8 | 59.0 | 60.0 | 2.0 |
| Year of AMI | |||||
| 1995-1999 | 28.4 | 23.8 | 26.7 | 26.0 | 1.4 |
| 2000-2004 | 29.5 | 28.8 | 27.9 | 28.4 | 1.0 |
| 2005-2009 | 23.7 | 25.6 | 24.8 | 24.3 | 1.1 |
| 2010-2013 | 18.4 | 21.8 | 20.6 | 21.2 | 1.6 |
| Income quintiles | |||||
| Q1 | 22.5 | 22.1 | 22.5 | 22.5 | 0 |
| Q2 | 21.5 | 21.3 | 21.5 | 21.2 | 0.68 |
| Q3 | 20.0 | 19.8 | 20.0 | 20.1 | 0.21 |
| Q4 | 18.7 | 18.7 | 18.7 | 18.8 | 0.23 |
| Q5 | 17.3 | 18.2 | 17.4 | 17.5 | 0.27 |
| Rural population | 16.0 | 16.3 | 15.9 | 15.7 | 0.42 |
| Charlson Comorbidity Index (>2) | 10.5 | 17.0 | 10.5 | 11.6 | 3.3 |
| ADG (10+) | 22.3 | 35.6 | 22.4 | 23.1 | 1.8 |
| Previous comorbidities | |||||
| Diabetes mellitus | 28.8 | 33.7 | 29.2 | 29.9 | 1.7 |
| Hypertension | 58.4 | 73.6 | 59.7 | 60.2 | 0.89 |
| Dyslipidemia | 39.3 | 39.4 | 39.4 | 39.2 | 0.40 |
| Heart failure | 15.5 | 26.5 | 16.5 | 17.5 | 2.7 |
| Stroke | 6.0 | 9.7 | 6.3 | 6.8 | 2.1 |
| PVD | 4.5 | 7.6 | 4.7 | 5.1 | 1.5 |
| Atrial fibrillation | 7.3 | 14.2 | 7.9 | 8.4 | 1.6 |
| Bradyarrhythmia | 2.9 | 5.7 | 3.1 | 3.3 | 1.1 |
| Other arrhythmia | 5.9 | 10.1 | 6.2 | 6.4 | 0.81 |
| Anemia | 18.9 | 34.6 | 20.2 | 21.7 | 3.6 |
| Renal disease | 9.8 | 18.4 | 10.6 | 11.8 | 4.0 |
| GI bleed | 9.8 | 17.7 | 10.5 | 11.0 | 1.4 |
| COPD | 23.2 | 34.4 | 24.2 | 25.6 | 3.4 |
| Prior coronary procedures | |||||
| Coronary angiography | 12.0 | 15.4 | 12.3 | 12.6 | 1.2 |
| PCI | 3.8 | 4.8 | 3.9 | 4.0 | 0.34 |
| CABG surgery | 3.9 | 4.8 | 4.0 | 4.2 | 0.67 |
| Baseline cardiovascular medications | |||||
| Clopidogrel | 3.9 | 6.8 | 4.1 | 4.2 | 0.46 |
| ACEi/ARB | 32.9 | 52.3 | 36.8 | 38.0 | 2.3 |
| Spironolactone | 11.9 | 20.1 | 12.6 | 13.1 | 1.6 |
| β-blockers | 29.0 | 47.3 | 30.6 | 31.4 | 1.8 |
| CCB | 29.9 | 48.6 | 31.5 | 32.5 | 2.1 |
| Lipid lowering agents | 24.2 | 36.3 | 25.3 | 25.9 | 1.5 |
| Diuretics | 19.3 | 34.9 | 20.7 | 21.8 | 2.8 |
| Nitrates | 26.4 | 44.1 | 28.0 | 28.8 | 1.8 |
| Oral anticoagulants | 8.5 | 16.2 | 9.2 | 9.9 | 2.6 |
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ADG, aggregated disease groups; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft surgery; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HF, heart failure; HR, hazard ratio; IPTW, inverse probability treatment weight; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.